We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Lets Roche Resume Avastin Trial Enrollment
FDA Lets Roche Resume Avastin Trial Enrollment
December 18, 2009
Roche has been notified by the FDA that it may resume enrolling patients in a Phase III clinical trial with its oncology drug Avastin to treat early-stage,
HER-2-negative breast cancer.